Valor202020212022202320242025TTMGastos comerciales, generales y administrativos———————Investigación y desarrollo———————Beneficio operativo———————Total de ingresos no operativos———————Gastos por intereses, netos de intereses capitalizados———————Ingresos no operativos, una vez deducidos los gastos por intereses———————Ingresos/gastos extraordinarios———————Beneficio antes de impuestos———————Participación en los beneficios———————Impuestos———————Participación minoritaria———————Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas———————Operaciones suspendidas———————Beneficio neto———————Ajuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas———————Beneficio básico por acción———————Beneficio por acción diluido———————Número medio de acciones ordinarias———————Acciones diluidas———————EBITDA———————EBIT———————Costo de los ingresos———————Otros costes de producción———————Amortización y depreciación (flujo de caja)———————
Fresenius Medical Care AG American Depositary Shares (Each repr
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease, which requires patients to undergo dialysis 3 times per week for the rest of their lives.
With a global headquarters in Bad Homburg vor der Höhe, Germany, and a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States. It also operates 42 production sites, the largest of which are in the U.S., Germany, and Japan.
The company is 32% owned by Fresenius and, as of 2020, generates around 50% of the group's revenue.
As of 2024, the company was ranked as #612 on the World's Best Employers list published by Forbes.